Citations

Showing 10 of 108083 citations.

Regulation of Inflammatory Bowel Disorder Inflammation by ST8Sia6
Crotts, Sydney B. , Shapiro, M., Rajcula, Matthew, Friedman, David J. , Shapiro, Michael J, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 60.15-60.15

10.4049/jimmunol.206.supp.60.15 Get It

Abstract Inflammatory bowel disorders (IBD), including Crohn’s disease and colitis, have a prevalence between 10–20%. IBD patients experience a reduced quality of life due to symptoms such as diarrhea, abdominal cramps, anal bleeding. The exact etiology of IBD is incompletely understood, but the immune response plays a critical role. Innate immune cells integrate the sum of stimulatory and inhibitory signals to determine overall activation. Solidifying the roles of pertinent proteins and their interactions is critical in mapping the immune response and understanding the implications of clinical treatment of IBD. ST8Sia6 is a sialic acid transferase which adds terminal a2,8 disialic acids to cell surface glycoproteins, and we have found that ST8Sia6 generates ligands for Siglec-2 and Siglec-E on innate immune cells, including colonic macrophages and neutrophils. These siglecs are inhibitory sialic acid-binding membrane receptors expressed on several immune cell subsets. Restraining ST8Sia6 should therefore enhance the immune response by reducing siglec-mediated inhibition. To examine this, our lab has generated a novel ST8Sia6 knockout (KO) mouse. At baseline these mice are healthy, but we have found that ST8Sia6 KO mice challenged with dextran sodium sulfate (DSS)-induced colitis lose weight and succumb to colonic inflammation significantly faster than their wildtype (WT) counterparts, particularly at low doses. ST8Sia6 KO mice exhibit increased histological damage and immune infiltration of the colon and small bowel as compared to WT controls. This data demonstrates a role for ST8Sia6 in regulating the hose immune response to inflammatory bowel disorders.
Metabolite-Based Microparticles Enhance the Metabolic Fitness of T cells
Wu, Christopher, Inamdar, Sahil , Acharya, Abhinav P , Curtis, Marion

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 27.18-27.18

10.4049/jimmunol.206.supp.27.18 Get It

Abstract Adoptive Cell Transfer (ACT) therapies have recently fostered excitement for the treatment of hematogenous cancers. However, efficacy has largely been stunted in the treatment of solid tumors, especially for ovarian cancer, in part due to nutrient restriction within the tumor microenvironment. We recently demonstrated that intracellular delivery of biodegradable microparticles (MPs) made from polymers of alpha-ketoglutarate modulated dendritic cell energy metabolism and immunophenotype, altering regulatory and helper T cell frequencies. To determine if continuous metabolite release from MPs would rescue T cell dysfunction in nutrient-poor, immunosuppressive conditions, we generated MPs of polymerized glycolytic and tricarboxylic acid cycle central-carbon metabolites. Flow cytometric analysis and confocal microscopy indicated that FITC-conjugated MPs were efficiently loaded into the cytoplasm of activated primary murine T cells via membrane adsorption or electroporation. The MPs were retained intracellularly and sustained proliferation of mouse T cells for over five days in vitro. Glycolysis and mitochondrial respiration stress tests using an Agilent Seahorse XFe96 Analyzer demonstrated that primary mouse CD8 T cells utilized the MPs as a metabolic substrate. In particular, MPs increased metabolic function, as indicated by increased spare respiratory capacity, glycolysis, and glycolytic capacity. The results of this study provide preliminary evidence in support of utilizing sustained-releasing particles of metabolic substrates for the metabolic reprogramming of immune cells used in ACT therapies. This strategy has potential to improve or expand the efficacy of existing ACT therapies for solid tumors.
Visualization of leukemic B cell clonal dynamics during therapy using tSNE
Welch, Baustin M.

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 12.14-12.14

10.4049/jimmunol.206.supp.12.14 Get It

Abstract Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD19+ CD5+ clonal B lymphocytes in the blood, bone marrow, and peripheral lymphoid organs. Many patients with CLL never receive treatment for the leukemia and therapy is typically only initiated upon progression of disease-related clinical complications. Treatment options for progressing patients range from chemoimmunotherapy (CIT) to small molecule inhibitors that target pro-survival signaling pathways in leukemic B cells, such as the BTK inhibitor ibrutinib. Although therapy regimens have improved, there is still no cure for CLL, in part due to clonal evolution of the leukemic B cell. The goal of this study is to document the clonal dynamics of CLL B cells at baseline and at response evaluation(s) for alterations in clonal architecture and expression of cell surface markers associated with therapy resistance using the single cell flow cytometry analysis tool, t-distributed stochastic neighbor embedding (t-SNE). Biobanked peripheral blood mononuclear cells were obtained from patients that underwent frontline CIT or ibrutinib, or secondary ibrutinib therapy. Fourteen parameter flow cytometry was performed and subjected to tSNE analysis to document CLL B cell clonal architecture and evolution in patients undergoing the various therapies. Profound differences in treatment responses and leukemic cell clonal dynamics were observed which may inform the discovery of novel biomarkers associated with therapy resistance.
Antigen presentation by CNS-resident microglia and macrophages regulates CD8 T cell infiltration of the brain during central nervous system (CNS) infection
Lipovsky, Chloe, Hansen, Michael, Johnson, Aaron J. , Goddery, Emma N. , Fain, Cori E. , Jin, Fang , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 11.18-11.18

10.4049/jimmunol.206.supp.11.18 Get It

Abstract CD8 T cell responses are essential for clearance of infections in the CNS but contribute to neuropathology. T cell interaction with antigen presenting cells (APCs) at CNS barriers is thought to allow activated antigen-specific T cells to infiltrate the CNS during neuroinflammation. However, the role of CNS-resident APCs during CD8 T cell infiltration of the CNS is unclear. To address this, we utilized Theiler’s murine encephalomyelitis virus (TMEV) and Plasmodium berghei ANKA (PbA) to assess the role of APCs during CD8 T cell responses to CNS infection in mice. During infection, we observed robust upregulation of MHC class I on microglia and brain associated macrophages (BAM). Microglia and BAMs were located in close proximity to inflamed vasculature where antigen presentation to T cells could occur. Thus, we hypothesized that microglia and BAMs are critical APCs for CNS infiltration of antigen specific CD8 T cells. To test this, we generated mice with inducible deletion of MHC class I on microglia and BAMs by crossing CX3CR1creERT2 mice with H-2Db or H-2Kb floxed mice (Db cKO or Kb cKO). We found that brain infiltrating virus-specific CD8 T cells were reduced in Db cKO mice compared to controls during TMEV infection, while peripheral priming of T cells was unaffected. Conversely, antigen-specific CD8 T cell infiltration was not impacted in Kb cKO mice infected with TMEV-OVA257–264. In Db cKO mice, brain-infiltrating CD8 T cells were increased during PbA induced experimental cerebral malaria (ECM), indicating a potential inhibitory role for CNS APCs. These results demonstrate that local antigen presentation by microglia/BAMs can both positively and negatively regulate CD8 T cell infiltration of the brain in discrete neurologic disease models.
Metabolic Control of T cell responses by HDAC3
Wilfahrt, Drew Nicholas, Kizerwetter, Monika , Lama, Jyoti , Rajcula, Matthew, Kennedy, Madeleine, Philips, Rachael L. , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 24.15-24.15

10.4049/jimmunol.206.supp.24.15 Get It

Abstract After activation, CD4+ T cells undergo metabolic modifications in order to orchestrate successful immune responses. In particular, naïve T cells shift to a more glycolysis-heavy metabolic program that produces the necessary metabolites for growth, division, and exertion of effector function. Histone Deacetylase 3 (HDAC3) has been shown to epigenetically regulate many T cell fate decisions and is also capable of post-translationally modifying non-histone proteins. Deletion of HDAC3 in mature CD4+ T cells using a distal Lck-Cre HDAC3 cKO mouse revealed a reduction in differentiated T-helper cell populations in vivo. In contrast, in vitro differentiation of HDAC3-deficient CD4+ T cells occurred normally, however, the numbers of T cells present within each culture was greatly diminished. CD3/CD28-stimulated HDAC3-deficient cells exhibited poor proliferation with decreased blastogenesis, decreased CD25 expression, and decreased IL-2 production. Signaling downstream of TCR is disrupted in the HDAC3-deficient T cells. HDAC3-deficient CD4+ T cells have an overabundance of Foxo1 protein, and diminished signaling downstream of mTOR, including reduced phosphorylation of Ribosomal Protein S6, and decreased expression of Egr2. Key transporters involved in cholesterol efflux, ABCA1 and ABCG1, were upregulated in HDAC3-deficient CD4+ T cells. Strikingly, the proliferation and blasting defects of HDAC3-deficient CD4+ T cells are restored with the addition of exogenous cholesterol, but the signaling defects remain. Thus, the failure of HDAC3-deficient CD4+ T cells to proliferate is due to alterations in cholesterol homeostasis.
Engagement of ICOS in tissues promotes establishment of CD8+ tissue-resident memory T cells
Huggins, Matthew A. , Lu, Hanbin, Wang, Haiguang , Mittelsteadt, Kristen , Campbell, Daniel , Peng, Changwei , Wanhainen, Kelsey M. , Georgiev, Hristo , Hogquist, Kristin Ann , Silva, Henrique Borges da , Jameson, Stephen C.

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 24.06-24.06

10.4049/jimmunol.206.supp.24.06 Get It

Abstract Resident memory T cells (TRM) provide localized protective immunity in non-lymphoid tissues, but the signals and interactions within non-lymphoid tissues involved in generating TRM are incompletely defined. Inducible T-cell costimulator (ICOS) is a costimulatory molecule with well elaborated roles in regulating differentiation of CD4+ T cell populations, its function in CD8+ T cells is largely unexplored. With acute infection models, we found that ICOS-deficient CD8+ T cells showed minimal defects in the initial effector expansion and the generation of recirculating memory subsets. However, consistent with its high expression in TRM, ICOS deficiency significantly compromised the establishment of CD8+ TRM cells in diverse non-lymphoid tissues. We further confirmed that rather than pre-programming the TRM fate during initial T cell priming, the interaction between ICOS ligand (ICOSL) and ICOS in the non-lymphoid tissues during CD8+ T cell recruitment is critical for efficient tissue retention and acquisition of tissue residency signatures. ICOS signaling through PI3K pathway is key for TRM generation and ICOS stimulation promotes downregulation of KLF2, a transcription factor that regulates T cell trafficking, in CD8+ T cells after entering non-lymphoid tissues. Altogether, our data illustrate that engagement of ICOS is one of the critical local costimulatory cues that promote the establishment of tissue-resident populations, with potential implication for therapeutic manipulation.
The purinergic receptor P2RX7 promotes the accumulation of effector CD4+ T cells in the lung parenchyma during hypervirulent mycobacterial infection
Carvalho, Igor Santiao, Alves-filho, Jose , Álvarez, José María , Lassounskaia, Elena L, Carvalho, Igor Santiago de, Bomfim, Caio César Barbosa , Santos, Gislane de Almeida , Melo, Bruno Marcel Silva de , Hirata, Mário Hiroyuki , Lassounskaia, Elena, Silva, Henrique Borges da , Lima, Maria Regina D’Império

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 16.26-16.26

10.4049/jimmunol.206.supp.16.26 Get It

Abstract CD4+ T cells are crucial to control pulmonary tuberculosis, but also favor uncontrolled inflammation in severe disease. Effective CD4+ T cell response to tuberculosis is related to tissue location: Lung-resident CD4+ T cells display higher effector function in comparison to circulating cells. Among the factors favoring T cell residency in non-lymphoid tissues, extracellular ATP sensing via P2RX7 is crucial for the generation of virus-specific resident memory CD8+ T cells. Yet, its role in CD4+ T cell non-lymphoid tissue residency has not been defined. Moreover, mycobacterial infection induces high extracellular ATP levels due to lung tissue damage, which is increased in response to hypervirulent strains. Here, we used P2rx7 ablation models to test the role of P2RX7 in CD4+T cell function in tuberculosis. In response to the hypervirulent Mycobacterium bovis MP287/03 strain, lung-resident WT CD4+ T cells express higher P2RX7 levels compared to circulating CD4+ T cells. Compared to WT mice, P2RX7-deficient (P2rx7−/−) mice display reduced numbers of antigen-specific (I-AbESAT-64-17) and IFN-γ-producing CD4+ T cells in the lung parenchyma. Using cell adoptive transfers, while recipient CD4-deficient mice transferred with CD4+ WT T cells are protected, mice that received CD4+P2rx7−/− T cells develop severe tuberculosis. Mechanistically, CD4+P2rx7−/− T cells have poorer accumulation and IFN-γ production in the lung parenchyma; moreover, they show reduced proliferation in situ. This defect in proliferation is exclusively observed in the lung, with no differences observed in draining lymph nodes. Together, our results show that P2RX7 promote the accumulation of protective CD4+ T cells in the lung during severe tuberculosis.
Machine learning-based risk stratification for mortality in patients with severe aortic regurgitation
Anand, Vidhu , Hu, H. M. , Weston, Alexander D. , Michelena, Héctor I. , Carter, Rickey E. , Hu, Hanwen, Michelena, Hector I , Carter, Rickey E , Hu, Hanwen, Scott, Christopher G. , Pislaru, Sorin V. , Pellikka, Patricia A.

Mayo Clinic

European Heart Journal - Digital Health | February 7, 2023 | Volume: 4 | Issue: 3 | Pages: 188-195

10.1093/ehjdh/ztad006 | PMID 37265866 Get It

Abstract Aims The current guidelines recommend aortic valve intervention in patients with severe aortic regurgitation (AR) with the onset of symptoms, left ventricular enlargement, or systolic dysfunction. Recent studies have suggested that we might be missing the window of early intervention in a significant number of patients by following the guidelines. Methods and results The overarching goal was to determine if machine learning (ML)-based algorithms could be trained to identify patients at risk for death from AR independent of aortic valve replacement (AVR). Models were trained with five-fold cross-validation on a dataset of 1035 patients, and performance was reported on an independent dataset of 207 patients. Optimal predictive performance was observed with a conditional random survival forest model. A subset of 19/41 variables was selected for inclusion in the final model. Variable selection was performed with 10-fold cross-validation using random survival forest model. The top variables included were age, body surface area, body mass index, diastolic blood pressure, New York Heart Association class, AVR, comorbidities, ejection fraction, end-diastolic volume, and end-systolic dimension, and the relative variable importance averaged across five splits of cross-validation in each repeat were evaluated. The concordance index for predicting survival of the best-performing model was 0.84 at 1 year, 0.86 at 2 years, and 0.87 overall, respectively. Conclusion Using common echocardiographic parameters and patient characteristics, we successfully trained multiple ML models to predict survival in patients with severe AR. This technique could be applied to identify high-risk patients who would benefit from early intervention, thereby improving patient outcomes.
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Roemeling, Christina A. Von , Doonan, Bently P. , Klippel, Kelena , Schultz, Daniel , Hoang-Minh, Lan , Trivedi, Vrunda , Li, Chenglong , Russell, Rylynn A. , Kanumuri, Raju S. , Sharma, Abhisheak , Mitchell, Duane A. , von Roemeling, Christina A , Tun, Han W , Mitchell, Duane A , Doonan, Bently , Tun, Han W.

Mayo Clinic

Clinical Cancer Research | February 7, 2023 | Volume: 29 | Issue: 9 | Pages: 1751-1762

10.1158/1078-0432.ccr-22-1682 | PMID 36749885 Get It

Abstract Purpose: An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier and their unique microenvironment. These challenges are most evident in cancers such as lymphoma and melanoma, which are typically responsive to treatment in systemic locations but resistant when established in the brain. We propose interleukin-1 receptor-associated kinase-4 (IRAK-4) as a potential target across these diseases and describe the activity and mechanism of oral IRAK-4 inhibitor CA-4948. Experimental Design: Human primary central nervous system lymphoma (PCNSL) and melanoma brain metastases (MBM) samples were analyzed for expression of IRAK-4 and downstream transcription pathways. We next determined the central nervous system (CNS) applicability of CA-4948 in naïve and tumor-bearing mice using models of PCNSL and MBM. The mechanistic effect on tumors and the tumor microenvironment was then analyzed. Results: Human PCNSL and MBM have high expression of IRAK-4, IRAK-1, and nuclear factor kappa B (NF-κB). This increase in inflammation results in reflexive inhibitory signaling. Similar profiles are observed in immunocompetent murine models. Treatment of tumor-bearing animals with CA-4948 results in the downregulation of mitogen-activated protein kinase (MAPK) signaling in addition to decreased NF-κB. These intracellular changes are associated with a survival advantage. Conclusions: IRAK-4 is an attractive target in PCNSL and MBM. The inhibition of IRAK-4 with CA-4948 downregulates the expression of important transcription factors involved in tumor growth and proliferation. CA-4948 is currently being investigated in clinical trials for relapsed and refractory lymphoma and warrants further translation into PCNSL and MBM.
Spiritual care department leaders’ response to racial reckoning in 2020 and 2021
Muehlhausen, Beth L. , Desjardins, Cate Michelle , Tata, Beba , Chappelle, Christa , DeLaney, Allison , Olszewski, Antonina , Szilagyi, Csaba , Fitchett, George , Tata-Mbeng, Beba Shensi , Delaney, Allison

Mayo Clinic

Journal of Health Care Chaplaincy | February 7, 2023 | Volume: 29 | Issue: 3 | Pages: 292-306

10.1080/08854726.2023.2167416 | PMID 36749157 Get It